Long-Acting HIV Treatment Maintains 94% Viral Suppression: IDWeek 2026 - European Medical Journal

Long-Acting HIV Treatment Maintains 94% Viral Suppression: IDWeek 2026 European Medical Journal Five years of U.S. real-world evidence reinforce the durable effectiveness and long-term persistence of ViiV Healthcare’s Cabenuva Business Wire Broadly neutralising antibody plus cabotegravir maintains viral suppression for at least a year Aidsmap TheBodyPro | Study findings make a case for an unusual long-acting ART pairing: cabotegravir plus lenacapavir European AIDS Treatment Group UCT advances injectable HIV treatment and prevention UCT News